NYSE:DGX Quest Diagnostics (DGX) Stock Price, News & Analysis $156.60 +2.22 (+1.44%) (As of 03:25 PM ET) Add Compare Share Share Today's Range$155.22▼$157.2350-Day Range$138.36▼$156.9752-Week Range$119.59▼$159.36Volume225,254 shsAverage Volume947,555 shsMarket Capitalization$17.43 billionP/E Ratio21.08Dividend Yield1.92%Price Target$154.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Quest Diagnostics alerts: Email Address Quest Diagnostics MarketRank™ Stock AnalysisAnalyst RatingHold2.31 Rating ScoreUpside/Downside1.6% Downside$154.33 Price TargetShort InterestHealthy2.30% of Float Sold ShortDividend StrengthModerateBased on Four FactorsSustainability-0.62Upright™ Environmental ScoreNews Sentiment1.15Based on 11 Articles This WeekInsider TradingSelling Shares$365,081 Sold Last QuarterProj. Earnings Growth7.76%From $8.89 to $9.58 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.89 out of 5 starsMedical Sector19th out of 927 stocksMedical Laboratories Industry2nd out of 18 stocks 2.2 Analyst's Opinion Consensus RatingQuest Diagnostics has received a consensus rating of Hold. The company's average rating score is 2.31, and is based on 4 buy ratings, 9 hold ratings, and no sell ratings.Amount of Analyst CoverageQuest Diagnostics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Quest Diagnostics' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted2.30% of the float of Quest Diagnostics has been sold short.Short Interest Ratio / Days to CoverQuest Diagnostics has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Quest Diagnostics has recently decreased by 8.60%, indicating that investor sentiment is improving significantly. Previous Next 2.5 Dividend Strength Dividend YieldQuest Diagnostics pays a meaningful dividend of 1.95%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthQuest Diagnostics does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Quest Diagnostics is 40.38%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Quest Diagnostics will have a dividend payout ratio of 31.32% next year. This indicates that Quest Diagnostics will be able to sustain or increase its dividend.Read more about Quest Diagnostics' dividend. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreQuest Diagnostics has received a 74.52% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Private clinical drug testing", "Private genetic testing services", and "Private oncology diagnostics services" products. See details.Environmental SustainabilityThe Environmental Impact score for Quest Diagnostics is -0.62. Previous Next 3.4 News and Social Media Coverage News SentimentQuest Diagnostics has a news sentiment score of 1.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Quest Diagnostics this week, compared to 9 articles on an average week.Search Interest2 people have searched for DGX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Quest Diagnostics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Quest Diagnostics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $365,081.00 in company stock.Percentage Held by InsidersOnly 0.79% of the stock of Quest Diagnostics is held by insiders.Percentage Held by Institutions88.06% of the stock of Quest Diagnostics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Quest Diagnostics' insider trading history. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Quest Diagnostics are expected to grow by 7.76% in the coming year, from $8.89 to $9.58 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Quest Diagnostics is 21.11, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 132.15.Price to Earnings Ratio vs. SectorThe P/E ratio of Quest Diagnostics is 21.11, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 131.16.Price to Earnings Growth RatioQuest Diagnostics has a PEG Ratio of 2.80. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioQuest Diagnostics has a P/B Ratio of 2.78. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Quest Diagnostics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Brownstone Research My big AI project…On Wednesday, September 25, I’m putting on my first crypto event in two years to unveil: the Perceptron. This is my AI project that I first conceived of shortly after I recommended Nvidia back in 2016.Just click here to register. About Quest Diagnostics Stock (NYSE:DGX)Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.Read More DGX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DGX Stock News HeadlinesAugust 31, 2024 | insidertrades.comKarthik Kuppusamy Sells 1,990 Shares of Quest Diagnostics Incorporated (NYSE:DGX) StockSeptember 16 at 8:51 AM | prnewswire.comQuest Diagnostics Completes Acquisition of Select Lab Assets from Allina HealthSeptember 16, 2024 | Brownstone Research (Ad) My big AI project…On Wednesday, September 25, I’m putting on my first crypto event in two years to unveil: the Perceptron. This is my AI project that I first conceived of shortly after I recommended Nvidia back in 2016.September 13 at 1:28 AM | finance.yahoo.comInvesting in Quest Diagnostics (NYSE:DGX) five years ago would have delivered you a 60% gainSeptember 12, 2024 | marketwatch.comQuest Diagnostics Inc. stock rises Wednesday, still underperforms marketSeptember 9, 2024 | marketwatch.comQuest Diagnostics Inc. stock rises Monday, still underperforms marketSeptember 3, 2024 | marketwatch.comQuest Diagnostics Inc. stock remains steady Tuesday, still outperforms marketAugust 30, 2024 | benzinga.comInsider Unloading: Karthik Kuppusamy Sells $304K Worth Of Quest Diagnostics SharesSeptember 16, 2024 | Brownstone Research (Ad) My big AI project…On Wednesday, September 25, I’m putting on my first crypto event in two years to unveil: the Perceptron. This is my AI project that I first conceived of shortly after I recommended Nvidia back in 2016.August 28, 2024 | markets.businessinsider.comQuest Diagnostics: Hold Rating Affirmed Amid Balanced Risk/Reward Profile and Premium ValuationAugust 28, 2024 | prnewswire.comQuest Diagnostics to Speak at the Morgan Stanley 22nd Annual Global Healthcare ConferenceAugust 27, 2024 | markets.businessinsider.comBarclays Remains a Hold on Quest Diagnostics (DGX)August 26, 2024 | prnewswire.comQuest Diagnostics Completes Acquisition of LifeLabs, Enhancing Access to Diagnostic InnovationAugust 21, 2024 | markets.businessinsider.comQuest Diagnostics To Buy University Hospitals' Outreach Laboratory ServicesAugust 21, 2024 | prnewswire.comQuest Diagnostics to Acquire University Hospitals' Outreach Laboratory Services BusinessAugust 15, 2024 | prnewswire.comQuest Diagnostics Prices $1.85 Billion of Senior NotesAugust 15, 2024 | prnewswire.comquesthealth.com Introduces 13 New Blood Tests to Identify Micronutrient DeficienciesAugust 14, 2024 | prnewswire.comQuest Diagnostics Declares Quarterly Cash DividendSee More Headlines Receive DGX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Quest Diagnostics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Ex-Dividend for 7/22 Dividend7/08/2024Dividend Payable7/22/2024Last Earnings7/23/2024Today9/16/2024Ex-Dividend for 10/21 Dividend10/04/2024Dividend Payable10/21/2024Next Earnings (Estimated)10/22/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Medical laboratories Sub-IndustryHealth Care Services Current SymbolNYSE:DGX CUSIP74834L10 CIK1022079 Webwww.questdiagnostics.com Phone(973) 520-2700Fax201-462-4169Employees48,000Year Founded1967Price Target and Rating Average Stock Price Target$154.33 High Stock Price Target$165.00 Low Stock Price Target$135.00 Potential Upside/Downside0.0%Consensus RatingHold Rating Score (0-4)2.31 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)$7.43 Trailing P/E Ratio20.78 Forward P/E Ratio17.37 P/E Growth2.8Net Income$854 million Net Margins8.99% Pretax Margin11.94% Return on Equity15.35% Return on Assets7.19% Debt Debt-to-Equity Ratio0.57 Current Ratio1.00 Quick Ratio0.91 Sales & Book Value Annual Sales$9.25 billion Price / Sales1.86 Cash Flow$12.81 per share Price / Cash Flow12.05 Book Value$56.41 per share Price / Book2.74Miscellaneous Outstanding Shares111,320,000Free Float110,214,000Market Cap$17.19 billion OptionableOptionable Beta0.89 Social Links Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. James E. Davis (Age 61)Chairman, CEO & President Comp: $2.88MMr. Sam A. Samad (Age 54)Executive VP & CFO Comp: $1.33MMr. Michael E. Prevoznik (Age 62)Senior VP & General Counsel Comp: $881.23kMs. Catherine T. Doherty (Age 61)Executive Vice President of Regional Businesses Comp: $1MMr. Karthik Kuppusamy Ph.D. (Age 54)Senior Vice President of Clinical Solutions Comp: $840.3kMr. Michael J. Deppe (Age 57)Senior VP, Corporate Controller & Chief Accounting Officer Mr. Murali BalakumarSenior VP, Chief Information & Digital OfficerMr. Shawn C. BevecVice President of Investor RelationsMs. Kristin Lee Wallace Esq.Senior VP & Chief Compliance OfficerMr. Gary D. SamuelsSenior VP & Chief Communications OfficerMore ExecutivesKey CompetitorsLaboratory Co. of AmericaNYSE:LHDaVitaNYSE:DVAChemedNYSE:CHER1 RCMNASDAQ:RCMCorVelNASDAQ:CRVLView All CompetitorsInsiders & InstitutionsSanctuary Advisors LLCBought 9,687 shares on 9/5/2024Ownership: 0.009%Karthik KuppusamySold 1,990 sharesTotal: $304,987.40 ($153.26/share)Teachers Retirement System of The State of KentuckySold 249 shares on 8/26/2024Ownership: 0.008%Cetera Investment AdvisersBought 243 shares on 8/22/2024Ownership: 0.015%Truist Financial CorpSold 1,372 shares on 8/21/2024Ownership: 0.017%View All Insider TransactionsView All Institutional Transactions DGX Stock Analysis - Frequently Asked Questions How have DGX shares performed this year? Quest Diagnostics' stock was trading at $137.88 at the beginning of 2024. Since then, DGX shares have increased by 13.8% and is now trading at $156.85. View the best growth stocks for 2024 here. How were Quest Diagnostics' earnings last quarter? Quest Diagnostics Incorporated (NYSE:DGX) posted its quarterly earnings data on Tuesday, July, 23rd. The medical research company reported $2.35 EPS for the quarter, topping the consensus estimate of $2.31 by $0.04. The company's revenue was up 2.5% on a year-over-year basis. Read the conference call transcript. How will Quest Diagnostics' stock buyback program work? Quest Diagnostics' Board of Directors authorized a share repurchase plan on Thursday, February 2nd 2023, which allows the company to repurchase $1,000,000,000 in shares, according to EventVestor. This means that the company could purchase up to 6% of its shares through open market purchases. Shares buyback plans are generally a sign that the company's management believes its stock is undervalued. Does Quest Diagnostics have any subsidiaries? Quest Diagnostics subsidiaries include MACL, Blueprint Genetics, PhenoPath Laboratories, ReproSource, California Laboratory Associates, Cleveland HeartLab, Cape Cod Healthcare - Business, and others. Who are Quest Diagnostics' major shareholders? Quest Diagnostics' top institutional investors include Victory Capital Management Inc. (3.49%), American Century Companies Inc. (2.57%), Davis Selected Advisers (2.15%) and Dimensional Fund Advisors LP (1.90%). Insiders that own company stock include Stephen H Rusckowski, Catherine T Doherty, Michael E Prevoznik, Michael J Deppe, Timothy M Ring, Vicky B Gregg, Karthik Kuppusamy and Mark E Delaney. View institutional ownership trends. How do I buy shares of Quest Diagnostics? Shares of DGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Quest Diagnostics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Quest Diagnostics investors own include Xtrackers California Municipal Bond ETF (CA), BlackRock (BLK), Johnson & Johnson (JNJ), Micron Technology (MU), Gilead Sciences (GILD), Pfizer (PFE) and Abbott Laboratories (ABT). This page (NYSE:DGX) was last updated on 9/16/2024 by MarketBeat.com Staff From Our PartnersBiden's Executive Order, Dems Digital Money Legislation, First Step ToDonald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans...Monetary Gold | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredIntroducing the PerceptronOn Wednesday, September 25, I’m putting on my first crypto event in two years to unveil: the Perceptron. Th...Brownstone Research | SponsoredBREAKING NEWS: AI Tech Now Used to Stop School ShootersTwo seconds. That's all it takes for Knightscope's Automated Gunshot Detection to notify authorities and map a...Market JAR | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredPrepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dav...American Hartford Gold Group | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Quest Diagnostics Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Quest Diagnostics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
